US53566P1093
© PR Newswire
16.12.2025
LCTX
LISTED
TLV
Beyond Insulin Pumps: Cell Therapies Unlock a $403B Cure Economy
News Preview
Issued on behalf of Avant Technologies Inc.Equity Insider News CommentaryVANCOUVER, BC, Dec. 16, 2025 /PRNewswire/ -- The cell therapy manufacturing sector reached a pivotal inflection point in late 2025, with contract development and manufacturing organizations capturing 67.5% market share as the industry transitions from boutique R&D operati...
Themefolio
Profiler
Peergroup
© PR Newswire
16.12.2025
LCTX
LISTED
TLV
Beyond Insulin Pumps: Cell Therapies Unlock a $403B Cure Economy
News Preview
Issued on behalf of Avant Technologies Inc.Equity Insider News CommentaryVANCOUVER, BC, Dec. 16, 2025 /CNW/ -- The cell therapy manufacturing sector reached a pivotal inflection point in late 2025, with contract development and manufacturing organizations capturing 67.5% market share as the industry transitions from boutique R&D operations to...
Themefolio
Profiler
Peergroup
© BusinessWire
06.11.2025
LCTX
LISTED
TLV
Lineage Cell Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update
News Preview
Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel allogeneic, or “off the shelf”, cell therapies for serious medical conditions, today reported its third quarter 2025 financial and operating results and will host a conference call today at 4:30 p.m. Eastern Time to discuss these...
Themefolio
Profiler
Peergroup
Worth to know
20.10.2025
Short Selling Radar
USA, Europe, Asia
Track Short Selling Activities worldwide
Knowing what matters
Short sale statistics, hedge fund activities and much more user-friendly information
© BusinessWire
30.10.2025
LCTX
LISTED
TLV
Lineage Cell Therapeutics to Report Third Quarter 2025 Financial Results and Provide Business Update on November 6, 2025
News Preview
Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic, or “off the shelf”, cell therapies for serious medical conditions, today announced that it will report its third quarter 2025 financial and operating results on Thursday, November 6, 2025, following the close of the U.S. fi...
Themefolio
Profiler
Peergroup
Swarmalpha i/o · The Event Futures Prediction X
20.10.2025
© BusinessWire
08.09.2025
LCTX
LISTED
TLV
Lineage Cell Therapeutics Initiates Cell Transplant Program In Type 1 Diabetes
News Preview
Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel allogeneic, or “off the shelf”, cell therapies for serious medical conditions, today announced the initiation of a new islet cell transplant program in Type 1 Diabetes (T1D). Specifically, the company aims to deploy its manufactu...
Themefolio
Profiler
Peergroup
© BusinessWire
02.09.2025
LCTX
LISTED
TLV
Lineage Cell Therapeutics to Present at September 2025 Investor Conferences
News Preview
Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel allogeneic, or “off the shelf”, cell therapies for serious neurological and ophthalmic conditions, today announced that Brian M. Culley, Lineage’s Chief Executive Officer, will be presenting at the H.C. Wainwright 27th Annual Glo...
Themefolio
Profiler
Peergroup
© BusinessWire
26.08.2025
LCTX
LISTED
TLV
Lineage Announces Research Collaboration With William Demant Invest to Develop ReSonance™ (ANP1) for Hearing Loss
News Preview
Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel allogeneic, or “off the shelf,” cell therapies for serious neurological and ophthalmic conditions, today announced that it has entered into a research collaboration with and through an investment from William Demant Invest A/S (W...
Themefolio
Profiler
Peergroup
© BusinessWire
23.06.2025
LCTX
LISTED
TLV
OpRegen® (RG6501) 36-Month Visual Acuity Results Featured at Clinical Trials at the Summit 2025
News Preview
Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel allogeneic, or “off the shelf”, cell therapies for serious neurological and ophthalmic conditions, today announced that 36-month results from patients enrolled in a Phase 1/2a clinical study (ClinicalTrials.gov Identifier: NCT022...
Themefolio
Profiler
Peergroup
© BusinessWire
05.06.2025
LCTX
LISTED
TLV
Lineage Cell Therapeutics Announces Updates to the 3rd Annual Spinal Cord Injury Investor Symposium
News Preview
Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel allogeneic, or “off the shelf”, cell therapies for serious neurological and ophthalmic conditions, today announced additional presenters to the 3rd Annual Spinal Cord Injury Investor Symposium ("3rd SCIIS"). The 3rd SCIIS will be...
Themefolio
Profiler
Peergroup
© BusinessWire
14.05.2025
LCTX
LISTED
TLV
Lineage to Present at 3rd Annual H.C. Wainwright BioConnect Investor Conference at Nasdaq NYC
News Preview
Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced that Brian M. Culley, Lineage’s Chief Executive Officer, will be presenting at the 3rd Annual H.C. Wainwright BioConnect Investor Conference, in a fireside chat hosted...
Themefolio
Profiler
Peergroup
© BusinessWire
13.05.2025
LCTX
LISTED
TLV
Lineage Cell Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update
News Preview
Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel allogeneic, or “off the shelf”, cell therapies for serious neurological and ophthalmic conditions, today reported its first quarter 2025 financial and operating results and will host a conference call today at 4:30 p.m. Eastern T...
Themefolio
Profiler
Peergroup
© BusinessWire
12.05.2025
LCTX
LISTED
TLV
RG6501 (OpRegen®) Phase 1/2a Clinical Study 36 Month Results to Be Featured at Clinical Trials at the Summit 2025
News Preview
Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for serious neurological conditions, today announced that 36-month results from patients enrolled in a Phase 1/2a clinical study (ClinicalTrials.gov Identifier: NCT02286089) of RG6501 (OpRegen) in patients wit...
Themefolio
Profiler
Peergroup
Advertisment
20.10.2025
© BusinessWire
01.05.2025
LCTX
LISTED
TLV
Lineage Cell Therapeutics to Report First Quarter 2025 Financial Results and Provide Business Update on May 13, 2025
News Preview
Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for serious neurological conditions, today announced that it will report its first quarter 2025 financial and operating results on Tuesday, May 13, 2025, following the close of the U.S. financial markets. Line...
Themefolio
Profiler
Peergroup
© BusinessWire
22.04.2025
LCTX
LISTED
TLV
Lineage Cell Therapeutics and the Christopher & Dana Reeve Foundation Proudly Announce the 3rd Annual Spinal Cord Injury Investor Symposium
News Preview
Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, and the Christopher & Dana Reeve Foundation, a non-profit organization dedicated to advancing innovative research and improving quality of life for individuals impacted by paralysi...
Themefolio
Profiler
Peergroup
© BusinessWire
21.04.2025
LCTX
LISTED
TLV
Lineage to Present at 2025 Eyecelerator Meeting Sponsored by the American Academy of Ophthalmology (AAO)
News Preview
Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced that Brian M. Culley, Lineage’s Chief Executive Officer, has been invited to join presenters from REGENXBIO Inc., Regenerative Patch Technologies, LLC, Neurotech Pharma...
Themefolio
Profiler
Peergroup
© BusinessWire
10.03.2025
LCTX
LISTED
TLV
Lineage Cell Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
News Preview
Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for serious neurological conditions, today reported its fourth quarter and full year 2024 financial and operating results and will host a conference call today at 4:30 p.m. Eastern Time to discuss these result...
Themefolio
Profiler
Peergroup
© BusinessWire
05.03.2025
LCTX
LISTED
TLV
Lineage Cell Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Business Update on March 10, 2025
News Preview
Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for serious neurological conditions, today announced that it will report its fourth quarter and full year 2024 financial and operating results on Monday, March 10, 2025, following the close of the U.S. financi...
Themefolio
Profiler
Peergroup
© BusinessWire
11.02.2025
LCTX
LISTED
TLV
Lineage Initiates Clinical Study of OPC1 for Spinal Cord Injury
News Preview
Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for serious neurological conditions, announced today that the Company has initiated the DOSED (Delivery of Oligodendrocyte Progenitor Cells (OPCs) for Spinal Cord Injury: Evaluation of a Novel Device) clinical...
Themefolio
Profiler
Peergroup
© BusinessWire
04.02.2025
LCTX
LISTED
TLV
Lineage Cell Therapeutics to Present at the Oppenheimer 35th Annual Healthcare Lifesciences Conference
News Preview
Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for serious neurological conditions, today announced that Brian M. Culley, Lineage’s Chief Executive Officer, will be presenting at the Oppenheimer 35th Annual Healthcare Lifesciences Conference on February 11...
Themefolio
Profiler
Peergroup
© BusinessWire
27.01.2025
LCTX
LISTED
TLV
Lineage Cell Therapeutics Announces Closing of Second Tranche of Previously Announced Registered Direct Offering
News Preview
Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced the closing of the second tranche of its previously announced registered direct offering of an aggregate of up to $66 million. The Company had previously received $24 m...
Themefolio
Profiler
Peergroup
© BusinessWire
06.01.2025
LCTX
LISTED
TLV
Lineage Cell Therapeutics Issues Letter to Stockholders
News Preview
Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today published a letter to shareholders highlighting the company’s recent achievements and outlook for 2025.
Dear Fellow Shareholders,
We hope you had a restful holiday season and...
Themefolio
Profiler
Peergroup
© BusinessWire
21.11.2024
LCTX
LISTED
TLV
Lineage Cell Therapeutics Announces First Closing of up to $66 Million Registered Direct Offering
News Preview
Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced the first closing of its previously announced registered direct offering for the purchase and sale of up to an aggregate of 39,473,688 of Lineage’s common shares and ac...
Themefolio
Profiler
Peergroup
© BusinessWire
20.11.2024
LCTX
LISTED
TLV
Lineage Cell Therapeutics Announces Pricing of up to $66 Million Registered Direct Offering
News Preview
Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced that it entered into definitive agreements with certain healthcare focused institutional investors and with Broadwood Partners, L.P. (“Broadwood”), an affiliate of Neal...
Themefolio
Profiler
Peergroup
© BusinessWire
14.11.2024
LCTX
LISTED
TLV
Lineage Cell Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update
News Preview
Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today reported its third quarter 2024 financial and operating results. The Company will host a conference call today at 4:30 p.m. Eastern Time to discuss these results and to provide a...
Themefolio
Profiler
Peergroup
© BusinessWire
07.11.2024
LCTX
LISTED
TLV
Lineage Cell Therapeutics to Report Third Quarter 2024 Financial Results and Provide Business Update on November 14, 2024
News Preview
Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced that it will report its third quarter 2024 financial and operating results on Thursday, November 14, 2024, following the close of the U.S. financial markets. Lineage ma...
Themefolio
Profiler
Peergroup
© BusinessWire
14.10.2024
LCTX
LISTED
TLV
Lineage Cell Therapeutics to Present at the Maxim Group 2024 Virtual Healthcare Summit
News Preview
Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced that Brian M. Culley, Lineage’s Chief Executive Officer, will be presenting at the Maxim Group 2024 Virtual Healthcare Summit, in a fireside chat hosted by Jason McCart...
Themefolio
Profiler
Peergroup
© BusinessWire
25.09.2024
LCTX
LISTED
TLV
OpRegen® (RG6501) Phase 1/2a Results to Be Featured at International Society for Stem Cell Research (ISSCR) 2024 Copenhagen International Symposium
News Preview
Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced that Brian M. Culley, Lineage’s Chief Executive Officer, will be presenting at the International Society for Stem Cell Research (ISSCR) 2024 Copenhagen International Sy...
Themefolio
Profiler
Peergroup
© BusinessWire
18.09.2024
LCTX
LISTED
TLV
Lineage Presents Preclinical Data on Its Auditory Neuronal Cell Transplant Program, ReSonance™, at the 59th Annual Inner Ear Biology Workshop
News Preview
Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today reported that preclinical results with ReSonance (ANP1), the Company’s auditory neuronal cell transplant for the treatment of hearing loss, were presented at the 59th Annual Inne...
Themefolio
Profiler
Peergroup
© BusinessWire
13.08.2024
LCTX
LISTED
TLV
Lineage Cell Therapeutics to Present at the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference
News Preview
Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced that Brian M. Culley, Lineage’s Chief Executive Officer, will be presenting at the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference being held on Thursday, A...
Themefolio
Profiler
Peergroup
© BusinessWire
08.08.2024
LCTX
LISTED
TLV
Lineage Cell Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update
News Preview
Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today reported its second quarter 2024 financial and operating results. The Company will host a conference call today at 4:30 p.m. Eastern Time to discuss these results and to provide...
Themefolio
Profiler
Peergroup
Long/Short | Fractionals | Margin | Hedge · 4 powerful Trading App | MT4.MT5.ACTIVTRADER | TradingViewplus
More information, click here
More sector specific news
Your Press Release is missing or you want share news over GICS11? Drop us a line.
